Quick Answer
Jasper Therapeutics, Inc. reported Common Stock Shares Outstanding of 28.00 million shares for the year ending 2025.
- Jasper Therapeutics, Inc. showed an increase of +86.4% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from Jasper Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2019: 691,773 shares | Q3 2020: 736,213 shares | Q3 2021: 37.82 million shares | Q1 2022: 37.87 million shares | Q2 2022: 37.98 million shares | Q3 2022: 37.98 million shares | Q1 2023: 109.43 million shares | Q2 2023: 110.80 million shares | Q3 2023: 110.85 million shares | Q1 2024: 15.09 million shares | Q2 2024: 15.11 million shares | Q3 2024: 15.00 million shares | Q1 2025: 15.02 million shares | Q2 2025: 16.22 million shares | Q3 2025: 27.98 million shares.
- Over the full 6 years of available data (2020 to 2025), Jasper Therapeutics, Inc.'s Common Stock Shares Outstanding has grown by 910.5%.
- Historical annual values: Fiscal year 2025: 28.00 million shares | Fiscal year 2024: 15.02 million shares | Fiscal year 2023: 11.16 million shares | Fiscal year 2022: 3.80 million shares | Fiscal year 2021: 37.86 million shares | Fiscal year 2020: 2.77 million shares.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: